Calcium antagonists in the post-myocardial infarction setting

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Current guidelines do not recommend calcium antagonists for secondary prevention post-myocardial infarction (MI).
• This recommendation stems from studies using short-acting agents without reperfusion therapy, though class differences were noted.
• Dihydropyridine calcium antagonists showed no benefit, unlike rate-lowering agents.

Purpose of the Study:

• To review the evidence for rate-lowering calcium antagonists (verapamil, diltiazem) in secondary prevention after acute myocardial infarction (MI).
• To evaluate their efficacy, particularly in patients intolerant to beta-blockers.
• To provide clinical practice suggestions based on trial data.

Main Methods:

• Review of large-scale clinical trials investigating verapamil and diltiazem post-MI.
• Analysis of outcomes including recurrent MI, mortality, and cardiac events.
• Consideration of patient subgroups (e.g., non-Q-wave MI, pulmonary congestion) and concurrent therapies (e.g., thrombolysis).

Main Results:

• Verapamil trials showed significant reduction in reinfarction with a trend towards reduced mortality.
• Diltiazem trials demonstrated significant reduction in reinfarction, particularly in specific patient groups, with no mortality benefit.
• The INTERCEPT trial indicated a non-significant reduction in cardiac events with sustained-release diltiazem post-thrombolysis.

Conclusions:

• Rate-lowering calcium antagonists (verapamil, diltiazem) show benefit in reducing recurrent MI post-MI.
• These agents are a viable option for secondary prevention in patients intolerant to beta-blockers.
• Further clinical practice guidelines may incorporate these findings for specific patient populations.